Jenkins BG - Search Results

1

Riluzole therapy in Huntington's disease (HD).

Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME. Rosas HD, et al. Among authors: jenkins bg. Mov Disord. 1999 Mar;14(2):326-30. doi: 10.1002/1531-8257(199903)14:2<326::aid-mds1019>3.0.co;2-q. Mov Disord. 1999. PMID: 10091628 Clinical Trial.

2

1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, Koroshetz WJ. Jenkins BG, et al. Neurology. 1998 May;50(5):1357-65. doi: 10.1212/wnl.50.5.1357. Neurology. 1998. PMID: 9595987

3

Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.

Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM. Rosas HD, et al. Among authors: jenkins bg. Neurology. 2003 May 27;60(10):1615-20. doi: 10.1212/01.wnl.0000065888.88988.6e. Neurology. 2003. PMID: 12771251

4

Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.

Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR. Jenkins BG, et al. Neurology. 1993 Dec;43(12):2689-95. doi: 10.1212/wnl.43.12.2689. Neurology. 1993. PMID: 8255479

5

Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.

Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Koroshetz WJ, et al. Among authors: jenkins bg. Ann Neurol. 1997 Feb;41(2):160-5. doi: 10.1002/ana.410410206. Ann Neurol. 1997. PMID: 9029064

6

Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Matthews RT, et al. Among authors: jenkins bg. J Neurosci. 1998 Jan 1;18(1):156-63. doi: 10.1523/JNEUROSCI.18-01-00156.1998. J Neurosci. 1998. PMID: 9412496 Free PMC article.

7

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. Hersch SM, et al. Neurology. 2006 Jan 24;66(2):250-2. doi: 10.1212/01.wnl.0000194318.74946.b6. Neurology. 2006. PMID: 16434666 Clinical Trial.

8

An integrated strategy for evaluation of metabolic and oxidative defects in neurodegenerative illness using magnetic resonance techniques.

Jenkins BG, Chen YI, Kuestermann E, Makris NM, Nguyen TV, Kraft E, Brownell AL, Rosas HD, Kennedy DN, Rosen BR, Koroshetz WJ, Beal MF. Jenkins BG, et al. Ann N Y Acad Sci. 1999;893:214-42. doi: 10.1111/j.1749-6632.1999.tb07828.x. Ann N Y Acad Sci. 1999. PMID: 10672240 Review.

9

Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.

Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Jenkins BG, et al. J Neurochem. 2000 May;74(5):2108-19. doi: 10.1046/j.1471-4159.2000.0742108.x. J Neurochem. 2000. PMID: 10800956 Free article.

10

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Ferrante RJ, et al. Among authors: jenkins bg. J Neurosci. 2000 Jun 15;20(12):4389-97. doi: 10.1523/JNEUROSCI.20-12-04389.2000. J Neurosci. 2000. PMID: 10844007 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

125 results

Search Page